The added value of Real World Evidence – Written by Kavitha Baruah
The 58th Annual Scientific Meeting of the British Society for Haematology has had a busy agenda across the last three days.
The principal theme for this year’s event was “Better Science, Better Treatment”. Each day’s sessions included content and discussions around the advancement of science in genomics, data and therapeutics to achieve better patient outcomes in haematological diseases.
We here at pH are very excited to be presenting our 14th poster at BSH today. This year’s poster describes the interim results of the TRAIT project – an ongoing research study to describe the ‘real world’ use of Thrombopoietin-Receptor Agonists in the management of immune thrombocytopenia in the UK. This study aims to evaluate the responses to thrombopoietin-receptor agonists in normal clinical practice and document the current treatment pathways for ITP in the UK. A Steering Committee for this including a number of Key Opinion Leaders from UK specialist centres, discussed the feasibility of the study design and ratified the study protocol at the UK ITP Forum meeting, held at the BSH Annual Scientific Meeting in April 2016.
In this year’s BSH conference, the results presented from the interim analysis of the TRAIT study are most interesting as they reveal that treatment responses of patients with primary immune thrombocytopenia to thrombopoietin-receptor agonists remain consistent with observations from clinical trials. The poster also highlights the UK wide variations in the type of thrombopoietin-receptor agonists received by patients with ITP.
Real world data recorded from routine clinical practice provide valuable insights and help complete the picture on healthcare delivery and patient outcomes.